Massimo Loda Curriculum Vitae

Transcription

1 Massimo Loda Curriculum Vitae Date Prepared: September 17, 2015 Name: Massimo Loda, M.D. Office Address: Departments of Pathology and Medical Oncology 450 Brookline Avenue, D 1536 Boston, MA Home Address: 9 Coolidge Road, Belmont, MA Work Phone: Work massimo_loda@dfci.harvard.edu Work FAX: Work Website: Place of Birth: Vigevano (PV), Italy November 19, 1955 Education Pre-clinical University of the Witwatersrand, Johannesburg, South Africa 1980 M.D., cum laude Medicine & Surgery University of Milan Milan, Italy Postdoctoral Training 07/80-06/85 Resident Emergency Surgery Ospedale Policlinico, University of Milan, Italy 07/85-06/86 Resident General Surgery Deaconess Hospital, Harvard Medical School, Boston, MA 07/86-06/88 Resident Anatomic Pathology Deaconess Hospital, Harvard Medical School 07/88-06/89 Fellow Anatomic and Molecular Pathology New England Medical Center, Tuft University, Boston, MA Licensure and Certification 1980 State licensure examination, Italy ECFMG examination FMGEMS examination 1985 Boards in Emergency Surgery, Italy 1986 FLEX Examination 1988 Massachusetts Medical License 1989 American Board of Anatomic Pathology (re-certification 2014)

2 Faculty Academic Appointments Assistant Research Professor Surgery Boston University, Boston, MA Instructor Pathology Tufts University, Boston MA Lecturer Pathology Residency Training Programs in Anatomic Pathology and Medical Oncology, University of Bologna, Bologna, Italy Instructor Pathology Harvard Medical School, Boston, MA Assistant Professor Pathology Harvard Medical School Associate Professor Pathology Harvard Medical School 2006 Professor Pathology Harvard Medical School 2007 Associate Member Broad Institute of Harvard and MIT, Cambridge, MA Visiting Professor in Molecular Oncology Division of Cancer Studies King s College London School of Medicine, London, UK 2015 Visiting Professor Pathology Course Universita Vita-Salute, Milan, Italy Appointments at Hospitals/Affiliated Institutions 05/90-03/92 Pathologist and Director 04/92-03/96 Staff Pathologist and Director Molecular Pathology Laboratory Immunohistochemistry Laboratory and Molecular Pathology Laboratory Institute of Anatomic Pathology, Ospedale Bellaria, Bologna, Italy New England Deaconess Hospital, Boston, MA 04/92-06/96 Director Tissue Bank New England Deaconess Hospital 07/96-06/98 Medical Director Molecular Diagnostic Laboratory Beth Israel Deaconess Medical Center 07/98-09/05 Director Molecular In Situ hybridization and Prostate Human Pathology Cores Dana-Farber/Harvard Comprehensive Cancer Center, Boston, MA 07/98-present Staff Pathologist Brigham & Women s Hospital, Boston, MA 1/06-present Director Center for Molecular Oncologic Pathology (CMOP) Dana-Farber Cancer Institute/Brigham & Women s Hospital, Boston, MA 07/07-06/10 Director Genito-urinary Pathology Service, Department of Pathology Brigham & Women s Hospital, Boston, MA 04/07-present Member Center for Cancer Genome Discovery (CCGD) Dana-Farber Cancer Institute, Boston, MA Other Professional Positions Staff Pathologist (Consultant) New England Baptist Hospital, Boston, MA Consultant Mitotix, Inc., Cambridge, MA Consultant Oncor, Inc., Gaithersburg, M.D Member, Scientific Advisory Board BIOGENIX, Inc., San Ramon, CA 1999 Member, External Advisory Board for Grant Proposal, Harvard School of Public Health, Boston, MA Prospective studies of diet and cancer in men and women Consultant GPC, Biotech, Inc., Cambridge, MA Consultant Vertex Pharmaceuticals, Cambridge, MA Member of the Scientific Advisory Board Impath, Inc., New York, NY Consultant Novartis Pharmaceuticals, Basel, Switzerland Member, External Advisory Board Program Project Grant Biology of the Prostate Cancer Prevention Trial (PI Scott Lippman, M.D.) 2

3 2004 Member, External Advisory Board, Genitourinary University of Southern California SPORE Grant, PI: John Stein & Richard Cote 2005-present Member, External Advisory Board Pacific NW Prostate Cancer SPORE, Fred Hutchinson Cancer Center, Seattle, WA 2006-present Member, Scientific Advisory Board Cell Signaling Technology, Danvers, MA 2007 Member, Scientific Advisory Board Champalimaud Foundation, Lisbon, Portugal, Cold Spring Harbor Laboratory, 2007 Member, External Advisory Board The Robert Wood Johnson Medical School, New Jersey Prostate Cancer SPORE Member, Scientific Advisory Board The DNA Repair Company (DNAR), Boston, MA 2007-present Member, Scientific Advisory Board Mitra Life Sciences, Inc., Bangalore, India Consultant Merck Pharmaceuticals, Boston, MA 2008-present Member, External Advisory Board UCLA Prostate Cancer SPORE, Los Angeles, CA 2008-present Consultant Infinity Pharmaceuticals, Cambridge, MA 2009 Consultant Myriad Genetics, Salt Lake City, UT 2010-present Member, Scientific Advisory Board Metamark, Cambridge, MA 2010-present Co-Chair, The Cancer Genome Atlas (TCGA) Prostate Disease Working Group National Cancer Institute, National Institutes of Health, Bethesda, MD Member, Integration Panel, Prostate Cancer Research Department of Defense Program (PCRP), Congressionally Directed Medical Research Program Member, Interrnal Advisory Board Beth Israel Deaconess Medical Center: Kidney Cancer SPORE, Boston, MA Member, Tissue-based Biomarker Assays Subcommittee (TBBA) National Cancer Institute, National Institutes of Health Member, Scientific Advisory Board, 5-year term Pezcoller Symposium, Trento Italy 2011-present 2011-present Scientific Advisory Board for the Prostate Cancer Research Consortiums programme grant to the Irish Cancer Society Member, Ad Hoc Search Committee for Pathology and Genetics Professor Recruitment Dublin, Ireland Harvard Medical School Boston, MA 2014 Member, New York Academy of Sciences Member, External Advisory Board UCSF Prostate Cancer SPORE, San Francisco, CA 2014 Member International Society of Urological Pathology Member, Tumor Cell Biology Study Section, NCI 2015 Member, Association of American Physicians Major Administrative Leadership Positions Local Director, Diagnostic Immunohistochemistry Laboratory Deaconess Hospital, Boston, MA and Diagnostic Molecular Pathology Laboratory Director, Diagnostic Molecular Pathology Laboratory Beth Israel Deaconess Medical Center Director, Genito-Urinary Pathology Service Brigham & Women s Hospital Regional Director, in situ Hybridization and Prostate Pathology Core Facilities 3 Dana-Farber/Harvard Comprehensive Cancer Center, Boston, MA

4 2006-present Director, Center for Molecular Oncologic Pathology (CMOP) Dana-Farber Cancer Institute/Brigham & Women s Hospital, Boston, MA Committee Service Local Member, Radiation Safety Committee New England Deaconess Hospital Institutional Review Board (IRB) Member, Human Genetic Research IRB Subcommittee New England Deaconess Hospital and Beth Israel Deaconess Medical Center Elected Member, Faculty Council Harvard Medical School Member, Subcommittee on admission of students in the Faculty of Medicine, M.D.-Ph.D. Program 2006 Chair, Search Committee for Assistant Professor of Pathology 2006 Member, Pathology Faculty Search Committee for Assistant Professor at the Department of Pathology Harvard Medical School Harvard Medical School Beth Israel Deaconess Medical School 2007 Chair, Promotion Committee to Professor of Surgery Harvard Medical School Member, Benjamin Castleman Award Committee United States and Canadian Academy of Pathology, Inc., (USCAP), Augusta, GA 2009 Co-Leader, Task Force on Personalized Medicine Dana-Farber/Brigham & Women s Hospital, Boston, MA 2009 Member, External Review, Department of Pathology, Brigham & Women s Hospital 2010 Member, Search Committee for Women s and Pre-natal Division Investigator, Assistant Professor of Pathology 2010 Chair, Ad Hoc Committee of evaluators for appointment of Professor of Medicine (Area of Excellence: Clinical Expertise with significant activity in Investigation) Member, Standing Committee on Promotions, Reappointments, and Appointments Brigham & Women s Hospital, Boston, MA Harvard Medical School Harvard Medical School and Massachusetts General Hospital Harvard Medical School 2010-present Member, Radiology Research Working Group Dana-Farber/Brigham and Women s Cancer Center (DF/BWCC) 2012-present Member, Dana-Farber Committee for Faculty Promotions and Appointments (DFCPA) Dana-Farber Cancer Center 2009 Member, Tissue-based Biomarker Assays Subcommittee Biomarkers Task Force, Investigational Drug Steering Committee (CTEP), National Cancer Institute 2010-present Co-Chair, The Cancer Genome Atlas (TCGA) Prostate Disease Working Group 4 National Cancer Institute, National Institutes of Health, Bethesda, MD

5 2016 Co-Chair, 2016 Annual Meeting Program Committee American Association of Cancer Research (AACR), Philadelphia, PA Thesis Advisory Committee Dissertation Defense of National and International graduate students 11/15/2011 Stacey Lynn Eggert Ph.D. Candidate in Biological and Biomedical Sciences - Harvard University Identification and Characterization of Genetic Variants Conveying Risk to Uterine Leiomyomata 12/5/2011 Dissertation Defense of Alexis Ramos Ph.D. Candidate in Biological and Biomedical Sciences - Harvard University Cancer Genome Characterization using DNA Sequencing and SNP Array Analysis 3/1/2015 Dissertation Defense of Margrethe Storm: Molecular mechanisms of androgen effects on prostate cancer cells Department of Biosciences, Faculty of Methematics and Natural Sciences, University of Oslo, Norway Professional Societies The US and Canadian Academy of Pathology, Member The American Association of Cancer Research, Member The New England Society of Pathologists, Member The Endocrine Pathology Society, Member American Society of Investigative Pathology, Member 2015 Member, Association of American Physicians Grant Review Activities 1994 VA Granting Office, Reviewer 1996 Chemoprevention Branch, National Cancer Institute, Ad-Hoc Reviewer 1996 Medical Research Council of Canada, Reviewer National Cancer Institute, Ad Hoc Reviewer Department of Defense, Prostate Cancer Research Program, Member, Study Section, Pathobiology 2003 Associazione Italiana Ricerca sul Cancro (AIRC), Reviewer Cancer Research UK, Reviewer 2005 Department of Defense, Prostate Cancer Research Program, Member, Study Section, Pathobiology NCI, Molecular Oncogenesis (MONC), Ad Hoc Member, Study Section 2005-present United States and Canadian Academy of Pathology (USCAP) , Abstract Review Board , Abstract Reviewer, Pathobiology section, USCAP 2007 Prevention, Control and Population Sciences, NCI, Ad Hoc member, Special Emphasis Panel 2008 Samuel Waxman Cancer Research Foundation, Reviewer Department of Defense, Congressionally Directed Medical Research Program, Member, Prostate Cancer Research Program, Integration Panel Member 2013 Quinquennial Review for Cancer Research UK, Prof. Caldas group. Cambridge, England Member of international review panel. 5

6 Editorial Activities Serve on Editorial Board for the following journals: American Journal of Clinical Pathology 1994-present 2005-present 2009-present Diagnostic Molecular Pathology Cell Division Laboratory Investigation Associate Editor, American Journal of Pathology American Journal of Pathology, Editorial Boad member Consulting Editor, BJU International Journal 2012-present Editorial Board, American Journal of Pathology Ad-Hoc Reviewer for the following Journals: Nature Science New England Journal of Medicine Cell Metabolism Journal of Clinical Oncology Nature Medicine Cancer Cell Oncogene Journal of Clinical Investigation Modern Pathology Cancer British Journal of Cancer Blood Journal of the National Cancer Institute Human Pathology Cancer Research The Prostate Breast Cancer Research Molecular Carcinogenesis British Journal of Urology Other and Former Editorial Roles Former Member, Editorial Board The Prostate Journal Former Member, Editorial Board Journal of Clinical Pathology Former Member, Editorial Board The American Journal of Oncology Review 2007 Former Member, Editorial Board Clinical and Translational Science (CTS) Former Senior Editor Clinical Cancer Research Former Member, Editorial Board American Journal of Translational Research Honors and Prizes 1980 MD, Summa cum laude University of Milan Academic Achievement 1995 CaP CURE Award Association for the Cure of Research 6

7 Cancer of the Prostate, Santa Monica, CA 1997 Stowell-Orbison Award US and Canadian Academy of Pathology 1997 CaP CURE Award Association for the Cure of 1998 The Claudia Adams Barr Investigator in Cancer Research Award Cancer of the Prostate Dana-Farber Cancer Institute 1998 The Daland Award The New England Cancer Society Worcester, MA 2001 CaP CURE Award Association for the Cure of Cancer of the Prostate 2003 CaP CURE Award Association for the Cure of Cancer of the Prostate 2003 Donald S. Coffey-CaP Association for the Cure of CURE Physician- Cancer of the Prostate Scientist Award Clinical/Research Research Research and Clinical Innovation Research Research Research Clinical/Research 2005 Prostate Cancer Foundation Research Award Prostate Cancer Foundation Research 2012 Challenge Award Prostate Cancer Foundation Research 2015 Nominated Officer President of the Republic of Italy Research (Knighthood) of the Order of the Star of Italy 2015 (Ufficiale dell'ordine della Stella d'italia) 2015 Elected Member Association of America Physicians Clinical/Research 2015 Nominated Member Tumor Cell Biology Study Section Reserach NCI (4 year term) Report of Funded and Unfunded Projects Funding Information Past Grants: NIH Endocrine factors in recovery from surgical trauma, Co-investigator University Hospital, Boston, MA, Principal Investigator Role of Interleukin 1 and hormones in the hepatic acute phase response Armed Forces Radiobiology Research Institute, Bethesda MD and Naval Blood Research Laboratories, Boston, MA, Co-investigator Combined radiation and burn injury, the role of primary excision and wound closure Ministero della Pubblica Istruzione, Rome, Italy, Consultant Medulloblastoma cell lines in vitro and in vivo Ministero della Sanità, Rome, Italy, Co-investigator HIV damage in the central nervous system. 7

8 Associazione Italiana Ricerca sul Cancro (AIRC), Milan, Italy, Co-investigator Point mutations in Gs proteins in thyroid neoplasms Associazione Italiana Ricerca sul Cancro, Co-investigator Study of homeobox sequence-harboring genes in growth and differentiation of primitive CNS neoplasms Serono, Geneva, Switzerland, Co-investigator Hormonal regulation of prostate cancer CaP CURE award, Prostate Cancer Foundation, Principal Investigator Role of MKP-1 in prostate cancer NIH - PO1, Principal Investigator, Pathology Core The pathobiology of colorectal cancer Oncor, Inc., Principal Investigator Evaluation of the Oncor HER-2/neu (ERBB2) gene amplification detection kit for the interphase detection of HER-2/neu (ERBB2) genomic sequences in human breast tissue for node-negative, primary breast cancer. Multistudy for FDA approval of the HER-2/neu (ERBB2) gene amplification detection kit. (Kit FDA approved Jan 1998) Mitotix, Inc. Principal Investigator CDC 25 expression in human tumors CaP CURE Foundation, Prostate Cancer Foundation, Principal Investigator Role of p27 in prostate cancer Beth Israel Deaconess Medical Center, West Campus, Principal Investigator In house grant for exploratory projects. Role of ubiquitin-proteasome pathway in prostate cancer Barr Investigator, Dana Farber Cancer Institute, Principal Investigator Role of MKP-1 in prostate cancer DOD-ARMY, Principal Investigator Androgen regulation of p27 in the normal and neoplastic prostate NIH/NCI RO1, Principal Investigator Isopeptidases, ubiquitin-degradation and prostate cancer NIH/NCI RO1 (UCLA - Harvard), Principal Investigator, subcontract Stem cell genes in human prostate growth and differentiation Massachusetts Department of Public Health, Principal Investigator Functional identification of prostate cancer genes directing carcinogenesis and tumor progression NIH UO1, Co-Investigator Gene expression analysis of cancers of the prostate and lung. Director s challenge RFA DFCI/Novartis Drug Discovery program grant, Principal Investigator Role of p63 in prostate development: an animal model NIH PO1, Principal Investigator The role of PTEN and the PI3K pathway in prostate cancer DF/HCC grant application, Principal Investigator Molecular in situ hybridization core. 8

9 DF/HCC grant application, Principal Investigator Human Pathology Core for Prostate Cancer Tisch Family Fund Award, Principal Investigator Therapeutic Potential of Cdk Inhibitors in Barrett s Associated Adenocarcinoma NIH P01, Co-Investigator of Project #2 Prospective study of Diet and Colorectal Neoplasia CaPCure Award, Principal Investigator The Isopeptidase USP2 as a Prostate Oncogene NIH/NCI CA90381 (Kantoff, DFCI), Principal Investigator of Pathology Core SPORE in Prostate Cancer Howard Hughes Medical Institute/SPORE, Principal Investigator Biomedical Research Support Program / Pilot Project Research Award. Validation of expression profiling at the cellular level DF/HCC grant for Core Technology Developments, Principal Investigator Biological Imaging Spectroscopy RFA on Cancer Detection, Dana Farber Cancer Institute, Principal Investigator Fatty Acid Profiles as Potential Biomarkers in Prostate Cancers DFCI/Novartis Drug Discovery Program, Principal Investigator USP2a and Fatty Acid Synthase (FAS) as molecular targets in prostate cancer Friends of Dana Farber Cancer Institute, Principal Investigator High Throughput Quantitation of Gene Expression in Tissue Microarray P01 Diet, Hormones, and Risk of Colorectal Cancer. Co-Investigator of Project #2 Dietary and Hormonal Determinants of Cancer in Women SPORE Pilot project, Principal Investigator USP2a as a molecular target in prostate cancer Prostate Cancer Foundation, Principal Investigator Fatty acid synthase as a metabolic oncogene in prostate cancer Nuclea, Inc., Principal Investigator Biomarkers in Cancer Novartis/DFCI Drug Development Program, Principal Investigator USP2a and Fatty Acid Synthase (FAS) as Molecular Targets in Prostate Cancer DOD Idea Development Award, Principal Investigator Mouse orthotopic xenographs of human prostate primary tumors Novartis -DFCI Drug Development Program, Principal Investigator Evaluation of drug target and pathway expression patterns in human tumors using quantitative in situ expression analysis tumors using quantitative in situ expression analysis NIH R01CA (Halperin, HMS), Co-Investigator Prostate Cancer Prevention by n-3 Unsaturated Fatty Acids NIH/NHLBI T32 HL (Gimbrone, BWH), Faculty 9

10 Vascular, Pulmonary and Renal Injury NIH/NCI P01 CA87969 (Hankinson, BWH), Co-Investigator Dietary and Hormonal Determinants of Cancer in Women: Project Merck & Co, Inc., Principal Investigator Joint development of fluorescence in situ hybridization (FISH) protocol to detect amplification status of MET gene in human tumors Samuel Waxman Foundation (Sawyers/MSKCC), Co-Investigator Elucidating Signatures of Pathway Activation and the Effects of Molecularly Targeted Therapy in Prostate Cancer Mouse Models and Patients Novartis-DFCI Drug Development Program, Co-Investigator (Loda lab, CMOP) AMPK, the Metabolic Syndrome and Prostate Cancer Friends of Dana-Farber, Co-Investigator (Loda lab) Qiagen BioRobot Universal System for Cancer Genomic Laboratories Prostate Cancer Foundation (Kantoff), Co-Invesgtigator CaP Cure Therapy Consortium Emphasis is to support the correlative and translational science that surrounds clinical trials and clinical investigation on prostate cancer mtor Therapy in Prostate Cancer: Signatures of Response and Biology of Resistance NIH/NCI R01CA (Febbo, Duke University), Co-Investigator Overall goal of the work proposed is to improve the care of men with prostate cancer by providing predictive markers and identify potentially synergistic combination therapy Research Fellowship in the Center for Molecular Oncologic Pathology (CMOP) Nuclea Biotechnology Projects involve novel applications of molecular cytogenetic technologies specific to prostate cancer DF/HCC Lung Cancer SPORE: Core A Tissue and Pathology Core NIH/NCI P50 CA90578 (Johnson, B/DFCI) Director, Pathology Core ($55,079, DFCI Only) The role of PTEN and P13K pathway in prostate cancer Pathology Core NIH/NCI P01 CA89021 (Cantley, L/BIDMC) Core Director $137,551 (Pathology Core) The aim of the project was to assess the role of P13K pathway in prostate cancer development utilizing animal models in human tumors. Past and Present Mentored Grants American-Italian Cancer Foundation Fellowship (D. DiVizio, Children s Hospital) Fatty acid synthase and caveolin-1 in prostate cancer Fulbright Scholarship (E. O Regan, BWH) Focusing on the cause of head and neck cancer in people younger than Harvard SPORE in Breast Cancer Fellowship 10

11 (E. Snyder, DFCI) Identification and characterization of putative breast cancer stem cell in situ using quantum dot-conjugated antibodies American-Italian Cancer Foundation Fellowship (Palescandolo, DFCI) Palmitoylation signature in prostate cancer cell lines University of Milan Fellowship (Benedettini, DFCI) The role of MET in metastasis: analysis of MET status and activation in metastatic gastric cancer or non small cell lung cancer (NSCLC) American-Italian Cancer Foundation Fellowship (Zadra, DFCI) AMPK: a potential target in prostate cancer TRP-22 project #122 RTOG Clinical Trials (Nguyen, BWH) The Impact of p27 Expression on Outcome of RTOG P.A.R.T. Investigatorship in Prostate Cancer Award (Priolo, DFCI) Integrative models to define metabolic signatures in human prostate tumors: toward new anti-metabolic approaches in cancer therapeutics Brigham & Women s Hospital Department of Pathology (A. Ligon, BWH) Eleanor and Miles Shore 50 th Anniversary Fellowship for Scholars in Medicine 2011 Joe Pashcow- PCF Young Investigator Award (K. Penney, HMS) Advance molecular Gleason signature into clinical validation and investigate the biological pathways that underlie tumor aggressiveness. If validated in biopsy tissue, 157-gene signature will improve outcome prediction and clinical decision making for PCa patients at the time of diagnosis The A. David Mazzone Career Development Award, DF/HCC (K. Penney, HSPH) The association of known prostate cancer geneticrisk variants with gene expression in normal prostate and tumor tissue as well as molecular subtypes of prostate cancer, defined by PTEN, MYC,and TMPRSS2:ERG. Will ascertain biological pathways that explain the link between genetic riskvariants and PCa Gleason-based mrna and metabolomic profiling to predict prostate cancer outcomes Prostate Cancer Foundation (K. Penney, HSPH) $75,000 To determine if the previously identified signature for lethal disease can be applied in the clinic, we will further validate and test its predictive ability in tissue at the time of diagnosis Characterizing the activation of PI3Kinase in prostate cancer Prostate Cancer Foundation (N. Martin, BWH) $75,000 To determine if the previously identified signature for lethal disease can be applied in the clinic, we will further validate and test its predictive ability in tissue at the time of diagnosis. Current Grant Funding: 09/26/08- Metabolic Syndrome, Fatty Acid Synthase and Prostate Cancer 11

12 07/31/13 12/14/11-12/13/14 12/01/05 11/30/12 04/15/06-06/30/15 NIH/NCI R01 CA renewal pending PI ($145,250, DFCI only) Administrative supplement award, 2009 The overarching hypothesis of this proposal is that high levels of FAS result from sustained AMPK inhibition, as occurs in the metabolic syndrome. To validate this hypothesis, we propose to utilize a multidisciplinary approach that combines cell biology, animal model studies, human prostate cancer samples and inherited genetic changes (utilizing large patient populations) that confer susceptibility to prostate cancer. Shedding light on stromal epithelial interactions in prostate cancer carcinogenesis and mortality Prostate Cancer Foundation Challenge award PI ($1,000,000) The proposed study will test and validate critical pathways in the stromal-epithelial environment associated with prostate carcinogenesis, illuminate alterations in pathways in the microenvironment that drive lethal disease, and develop novel bioinformatic tools to characterize stromal-epithelial cross-talk. We propose to integrate genome wide mrna and mirna expression data in cohorts from the US, Sweden and Ireland, and to translate results to detect novel chemopreventive and therapeutic strategies. Dana-Farber/Harvard Comprehensive Cancer Center: Pathology Core NIH/NCI P30 CA06516 (Benz, E/DFCI) The goals of this grant are to develop and maintain clinical/laboratory research programs of high quality related to the biology, cause and prevention, diagnosis and treatment of cancer; to serve as the major cancer center in the Harvard-Longwood Medical Area; to play a leadership role for cancer research and patient care in New England; and teaching/training of students, interns, residents, fellows/post-docs and graduate students. Genetics and Biology of Pancreatic Ductal Adenocarcinoma Experimental Pathology Core B NIH/NCI P01 CA (DePinho, R/DFCI) Director, Pathology Core (NCE) The goal of this P01 is to further elucidate the genetics and biology of the disease to a level that will guide the rational development of effective targeted agents, alone and in combination. 08/31/07 06/30/12 09/01/07-06/30/13 09/01/07-06/30/13 DF/HCC SPORE in Gastrointestinal Cancer: Core 2 Tissue and Pathology Core (NCE) NIH/NCI P50 CA (Fuchs, C/DFCI) The main goal of the Specialized Program of ResearchExcellence (SPORE) of Gastrointestinal Cancer is the translation of biological and technological advances into improvements in prevention, diagnostics, predictors of outcome, and avances in the treatment of gastrointestinal malignancies. DF/HCC SPORE in Prostate Cancer: Pathology Core (NCE) NIH/NCI P50 CA90381 (Kantoff, P/DFCI) Director, Pathology Core The major aims of this coare are to 1) provide a tissue and blood repository for use by SPORE investigators, 2) to provide research pathology services to SPORE investigators, including histology, immunochemistry, in situ hybridization, computer-assisted image analysis, laser capture microdissection, and the generation of and access to tissue microarrays. DF/HCC SPORE in Prostate Cancer: Pathology Core (NCE) NIH/NCI P50 CA90381 (Kantoff, P/DFCI) Co-Director, Project 3 TMPRSS2:ERG and SPINK1 in Lethal Prostate Cancer The overall hypothesis is that there are three mutually exclusive PCa subtypes: TMPRSS2: ERG positive, SPINK1 positive and Fusion/SPINK1 negative. An understanding of lethal PCa in the context of TMPRSS2: ERG and SPINK1 molecular alterations is currently lacking. The project proposes a comprehensive study 12

13 utilizing the Physicians Health Study and Health Professionals Follow-up Study among 1,500 men with PCa, of whom 175 developed lethal disease. 09/30/09-08/31/14 03/03/09-1/31/14 05/01/10-04/30/15 05/01/10-02/28/14 02/01/10 1/31/13 Targeting Tumor Suppressor Phosphatases for Cancer Therapy NIH/NCI U01 CA (PI: Pandolfi) This application aims to characterize the role of critical tumor suppressor phosphatases in human cancer and exploit the therapeutic potential of a novel type of senescence mechanism that we have discovered to arise in response to their acute inactivation. The project focuses on the potential for the development of novel therapies for the treatment of cancer through the targeting of the cancer stem cell. Sex Hormones and the TMPRSS2: ERG Fusion in Prostate Cancer progression NIH/NCI R01 CA (Mucci, BWH) Site PI The overall aim is to determine how SPINK1 and TMPRSS2: ERG fusion define the lethal phenotype of PCa and will estimate the utility of these molecular subtypes on risk stratification. Prognostic and Predictive Biomarkers Research Nuclea Biotechnology PI ($474,090) Overall goal is to develop a biomedical database of prognostic/predictive biomarkers derived from IHC survey of tumor microarrays, for use in diagnostics. Growth Factors and Lethal Prostate Cancer Signature R01CA (Stampfer, M/BWH) PI of subcontract The proposal is to apply a novel but proven high-throughput profiling technology to assess RNA expression in archival tumor tissue using a 24,000 gene platform. The overall goal is to distinguish prostate cancers that are incolent, and can safely be left untreated, from those that are potentially lethal and require aggressive therapy. The Cause and Consequence of Centrosome and Ploidy Abnormalities in Human Cancer using Barrett s Esophagus as a Model HMS Portugal Program (Golan/HMS) The overall goal is to define the relationship between centrosome abnormalities, known defects in genes and global changes in chromosome content. specific 09/12/11 7/31/16 Validation of Digital Morphometry for Cancer Risk in Benign Prostate Biopsies NIH/NCI R01 CA (Gann, P/U-ILL) $15,746 Aims: 1) To determine the effects of dutasteride (vs. placebo) on both nuclear and architectural features in benign tissue; 2) To determine whether a multivariable treatment-response score differs between subjects who develop PCa while on dutasteride and those who do not; and 3) To determine the magnitude of association between nuclear phenotype in benign biopsies, and subsequent risk of PCa in untreated men at elevated risk. 07/01/12 6/30/14 Developing a Blood-based Metabolomic Signature of Gleason Score A David Mazzone Awards Program.60 Calendar Months Principal Investigator ($50,000) We propose to perform metabolic profiling on blood collected before and after RP; comparisons between these samples can help confirm that significant metabolites are truly influenced by the 13

14 tumor (or the prostate) and not other characteristics. 09/30/13 Toward the Practice of Precision Medicine: A Biomarker Validation Coordinating Center 09/29/16 DOD W81XWH Principal Investogator To revolutionize the clinical management of prostate cancer to enable the practice of precision medicine in the near term by developing analytically validated assays for predictive biomarkers of sensitivity to AR and PI3K inhibitors for use in prospective clinical trials at all points in the disease 07/01/14 6/30/19 DF/HCC SPORE in Prostate Cancer: Pathology Core NIH/NCI P50 CA90381 (Kantoff, P/DFCI) Director, Pathology Core The major aims of this coare are to 1) provide a tissue and blood repository for use by SPORE investigators, 2) to provide research pathology services to SPORE investigators, including histology, immunochemistry, in situ hybridization, computer-assisted image analysis, laser capture microdissection, and the generation of and access to tissue microarrays. 07/01/14 6/30/19 DF/HCC SPORE in Prostate Cancer NIH/NCI P50 CA90381 (Kantoff, P/DFCI) Principal Investigator, Project 2 We propose to build upon our promising expression profiling findings with the following aims: 1) Preparation and testing of Gleason signature of lethal disease for clinical use, 2) Metabolomics of Gleason grade in tumor as predictor of lethal disease, and 3) Metabolomics of Gleason grade in serum as biomarker for upgrading. 07/01/14 6/30/19 DF/HCC SPORE in Gastrointestinal Cancer: Core 2 Tissue and Pathology Core NIH/NCI P50 CA (Fuchs, C/DFCI Core Director ($147,790) The main goal of the Specialized Program of ResearchExcellence (SPORE) of Gastrointestinal Cancer is the translation of biological and technological advances into improvements in prevention, diagnostics, predictors of outcome, and avances in the treatment of gastrointestinal malignancies. 7/01/14 06/30/17 DoD Synergy Award PC (Loda) PI DFCI, U. Mahmood (PI, MGH) $700,000 In vivo Targeting and Imaging of the lipogenic Phenotype of Prostate Cancer Principal Investigator The goals of this project are to assess whether AMPK activation inhibits castration-resistant prostate cancer (CRPC) growth in vivo. To investigate the biographic relevance of combining AMPK activators or FASN inhibitors with AR signaling inhibitors as a synergic therapeutic strategy for CRPC. Report of Local Teaching and Training Teaching of Students in Courses Pathology Laboratory tutor Tufts University School of Medicine, Boston, MA Medical students 1-5 hours daily for the duration of the course 14

15 Faculty member 4th, 5th, 7th, 9th Molecular Pathology workshops Tufts University School of Medicine 4 day course Laboratory Leader: Identity Microbes and Defense Harvard Medical School 50 Medical Students 4-6 hours before each session to present ½ hour lecture and go over slides with Medical Students 1995 Soma Weiss student research assembly supervised project for medical students entitled Expression of somatostatin receptors 1-4 in colorectal neoplasms Poster Presentation Harvard Medical School Supervised project for medical students 1997 Tutor, HMS Pathology course, Peabody Society Harvard Medical School 8-10 Medical Students 4-6 hours before each tutorial session Yearly lecture to the Division of Health Science and Technology HST: Frontiers: novel probes of cell function (Combined Harvard/MIT human Pathology Course) present Director of yearly Boot-Camp Course: Molecular Pathology of Cancer : Lecturer and lead faculty for 2-week lecture series Harvard Graduate Ph.D. Students Harvard Medical School 1 hour per lecture Harvard Medical School 30 hours 2009-present AACR - Translational Cancer Research for Basic Scientists Workshop. Diagnostic Molecular Pathology 1 day/year Formal Teaching of Residents, Clinical Fellows and Research Fellows (post-docs) Resident Training Deaconess Hospital 18 residents ~10 hours daily every week Lecturer in Pathology, Residency training program University of Bologna School of Medicine, Bologna, in Anatomic Pathology and Medical Oncology Italy Medical Students and residents hours to prepare 4-5 lectures Resident Training Beth Israel Deaconess Medical Center 38 residents ~10 hours daily every week Director, Diagnostic Molecular Pathology Laboratory Formal resident rotations within the lab; Taught a series of 8 lectures per year on Molecular Pathology Beth Israel Deaconess Medical Center Formal rotations were in one-month durations, also lectured on a weekly basis as part of the Clinical Pathology lecture series Resident Training University of Bologna, Bologna, Italy 12 residents ~5 hours daily every week 1998-present Resident Training Brigham & Women s Hospital 41 residents 1-5 hours daily every week on service plus 3 teaching lectures per year on genito-urinary pathology 1998-present Director, Center for Molecular Oncologic Pathology Dana-Farber Cancer Institute and Brigham & Women s Hospital 15

16 1998-present As a BWH Faculty member, I am responsible for the interviewing and recruitment of pathology residents Genitourinary Pathology Fellows Dana-Farber Cancer Institute and Brigham & Women s Hospital 1-2 hours weekly Clinical Supervisory and Training Responsibilities Director, Diagnostic Immunohistochemistry Laboratory; Director, Diagnostic Molecular Pathology Laboratory / Deaconess Hospital Director, Diagnostic Molecular Pathology Laboratory / Beth Israel Deaconess Medical Center Director of In Situ Hybridization and Prostate Pathology Core facilities / Dana-Farber/Harvard Cancer Center Director, Genito-Urinary Pathology service, Department of Pathology, Brigham & Women s Hospital 15 hours per week 20 hours per week 20 hours per week 5 hours per week Laboratory and Other Research Supervisory and Training Responsibilities Director, Diagnostic Immunohistochemistry Laboratory; Director, Diagnostic Molecular Pathology Laboratory / Deaconess Hospital 15 hours per week Director, Diagnostic Molecular Pathology Laboratory / Beth Israel Deaconess Medical Center Director of In Situ Hybridization and Prostate Pathology Core facilities / Dana-Farber/Harvard Cancer Center 20 hours per week 20 hours per week 2006-present Director, Center for Molecular Oncologic Pathology (CMOP), Dana-Farber Cancer Institute/Brigham and Women s Hospital 15 hours per week Director, Genito-Urinary Pathology service, Department of Pathology, Brigham & Women s Hospital 5 hours per week 1992-present Supervision of post-docs and graduate students in the lab, Dana-Farber Cancer Institute Daily Mentorship Formally Supervised Trainees Paola Capodieci, Ph.D. / Investigator III, Novartis, Cambridge, MA. Project title: MKP1 in different Cancer Types / Source of funding: NIH grant Cristina Magi-Galluzzi, M.D. / Professor of Pathology, Case Western Reserve University, Director of genito-urinary pathology service, Cleveland Clinic, Cleveland, OH Project Title: Role of Mitogen activated protein kinase phosphatase 1 (MKP-1) in prostate cancer / Source of funding: Industry sponsored research (PI: M.L.) Mira Mandoki, Ph.D. / Assistant professor, Department of Pathology and Forensic Veterinary Medicine, Faculty of Veterinary Science, Szent Istvan University, Hungary Project Title: Molecular diagnostic work: - detection of Factor V. Leiden mutation by PCR and RFLP, - detection of hepatitis C with Amplicor HCV Monitor (Roche) test, - in situ hybridization: HPV. Research projects: - C\EBP alpha, - prolactin receptor in human prostate cancer / Source of Funding: Molecular 16

17 diagnostic laboratory (Dr. Loda) Sabina Signoretti, M.D. / Independent Investigator and Associate Professor of Pathology, Brigham & Women s Hospital Project Title: p63 and prostate stem cells: an animal model / Source of funding: PO1 (PI: Cantley, BIDMC), SPORE (PI: Kantoff, DFCI), Novartis Investigator grant (PI: M.L.), DOD (New Investigator award with Dr. Signoretti as PI while in my lab) Douglas Lin, M.D., Ph.D. / Attending Pathology Department, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA Project Titile: SKP2 and its role in Prostate Cancer. Currently Resident in Pathology, Brigham and Women s Hospital Edgard Graner, D.D.S., Ph.D. / Associate Professor, Department of Oral Diagnosis, School of Dentistry of Piracicaba, University of Campinas (UNICAMP), State of Sao Paulo, Brazil, Av. Limeira 901, CP 52, Areao, Piracicaba, SP, Brazil CEP " Project Title: Discovery of novel de-ubiquitinating enzymes in prostate cancer / Source of funding: RO1 (PI: M.L.) Giulia Cangi, Ph.D. / Staff Scientist and Investigator, Department of Pathology, University Vita e Salute, S. Raffaele Hospital, Milan, Italy Project Title: Role of the dual-specificity phosphatase cdc25a in breast cancer / Source of funding: RO1 (PI: M.L.) Sabrina Rossi, M.D. / Staff Pathologist, Ospedale Ca Foncello, Treviso, Italy Project Title: Expression profiling of Fatty Acid Synthase expressing prostate carcinomas / Source of funding: PO1 (PI: Cantley, BIDMC) David Waltregny, M.D., Ph.D. / Academic Urologist, Professor of Pathology, University Hospital of Liege, Belgium Project Title: p27 regulation in a rat model of castration and testosterone-induced prostate regeneration / Source of funding: DOD (PI: M.L.) George Thomas, M.D. / Former position: Assistant Professor of Pathology, UCLA School of Medicine; Reader in Molecular Pathology, Chester Beatty Laboratories and The Royal Marsden Hospital, London and Sutton Currently: Surgical Pathologist: Oregon Health & Science University (OHSU), Portland, OR Project title: Role of p27 in the development of colon metastases in human tumors / Source of funding: RO1 (Massimo Loda, PI) 2001 Alessia Baccarini, Ph.D. / Instructor, Genetics and Genomic Sciences, Mt. Sinai School of Medicine, New York, NY Project Title: Analysis of CKS1 gene in prostate tissue Shuji Ogino, M.D., Ph.D. / Associate Professor of Pathology (BWH and Dana Farber Cancer Institute) Project Title: Molecular Pathology and Epidemiology of Colorectal Neoplasias / Source of Funding: PPGs (PIs, Willett, Colditz), R01 (PI, Fuchs) Mirna Lechpammer, M.D., Ph.D. / Fellow in Neuropathology, BWH Project Title: Chemoprevention of Barrett s Associated Adenocarcinoma by cdk inhibitors in a mouse model / Source of funding: Tisch grant Antonella Baron, Ph.D. / Postdoctoral Fellow- Laboratory of Urological Malignancies at Venetian Institute of Molecular Medicine (VIMM), Padua, Italy Project Title: Analysis of CKS1 gene in prostate tissue. / Source of Funding: NIH Grant Dan Tang, M.D., Ph.D. / Internal Medicine Physician, Mount Auburn Hospital, Cambridge, MA Project Title: The USP2a isopeptidase in prostate cancer 17

18 Toshiro Migita, M.D., Ph.D. / Research associate, Japanese Foundation for Cancer Research, The Cancer Institute of JFCR, Department of Pathology, Japan Project Title: Fatty acid synthase as an oncogene in prostate cancer. / Source of Funding: Prostate Cancer Foundation Wei Huang, M.D. /Assistant Professor, Dept. of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI Clinical Role: Genitourinary Fellow, Department of Pathology, Brigham and Women s Hospital Dolores Divizio, M.D., Ph.D. /Staff Scientist, Children s Hospital, Boston, MA Project Title: Fatty acid synthase and caveolin-1 in prostate cancer Carmen Priolo, M.D., Ph.D. / Instructor in Medicine, Harvard Medical School and Faculty member, Pulmonary and Critical Care Medicine (PCCM) Division at Brigham and Women s Hospital Project Title: Integrative models to define metabolic signatures in human prostate tumors: toward new antimetabolic approaches in cancer therapeutics. / Source of Funding: P.A.R.T Investigatorship in Prostate Cancer Award Tarek Bismar, M.D., Ph.D. / Associate Professor, University of Calgary, Faculty of Medicine, Calgary, AB Clinical Role: Genitourinary Fellow, Department of Pathology, Brigham and Women s Hospital Stephen Finn, M.D., Ph.D. / Associate Professor, University of Dublin Trinity College and St. James s Hospital. Project title: Quantum dot applications in pathology. / Source of Funding: Center for Molecular Oncology Pathology (CMOP) Stacy Ruiz, Ph.D. / Associate Director, Product Development, Reata Pharmaceuticals, Dallas, TX Project title: The role of AMPK as a therapeutic target for treating prostate cancer Zhiqian Liu, Ph.D. / Scientist, Biogen Idec, Boston, MA Project Title: The role of USP2a in EGFR endocytosis / Source of Funding: DOD Grant (Loda) 2006 Richard Mollow / Dr. Loda served as Mr. Mollow s thesis advisor at Harvard Extension School Thesis title: Use of Second Generation Monoclonal Immunoassay to Improve Sensitivity and Specificity in Prostate Cancer Screening for American Males Rosina Lis, M.D., Ph.D. / Research Scientist/ DF/BWH Center for Molecular Oncologic Pathology Project Titles: 1) DF/HCC SPORE in Gastrointestinal Cancer: Core 2 Tissue and Pathology Core, 2) Multi-Spectral Imaging Research Fellowship. / Source of Funding: 1) NIH/NCI: DF/HCC SPORE in Gastrointestinal - Core 2, 2) Industry: Nuclea Biomarkers, LLC Giuseppe Fedele, M.D. / Senior resident in Psychiatry, Mount Sinai School of Medicine, NY Project Title: Use of genetically engineered mouse models to determine the role and interactions of Fatty Acid Synthase and the master energy regulator AMPK in prostate cancer pathogenesis. / Source of Funding: GELB Center for Genitourinary Oncology, Dana-Farber Cancer Elisa Benedettini, Ph.D. / Research Fellow, Bufalini Hospital, Cesana, Italy Project Title: The role of MET in metastasis: analysis of MET status and activation in metastatic gastric cancer or non small cell lung cancer (NSCLC) patients. / Source of Funding: Fellowship from University of Milan 2006-present Ewa Sicinska, M.D. / Senior Research Scientist, CMOP Project: Mouse xenograft model of human sarcoma, DF/BWH CMOP / Source of Funding: Center for Molecular Oncology Pathology (CMOP) 2006 Emanuele Palescandolo, Ph.D. / Research Scientist and Group Leader, Center for Cancer Genome Discovery, CCGD, Currently, group leader, Leuven University, Belgium Project Title: Palmitoylation signature in prostate cancer cell lines. / Source of Funding: AICF Fellowship 18

19 Summer, present Esther O Regan, Ph.D. / Assistant Professor of Pathology, Trinity College, Dublin, Ireland. Awarded Fulbright scholar status to continue her work on head and neck carcinoma with Dr. Massimo Loda at DFCI. / Source of Funding: Center for Molecular Oncology Pathology (CMOP) Giorgia Zadra, Ph.D. / Postdoctoral Fellow, Loda lab. Currently Instructor in Pathology, Department of Pathology, Brigham & Women s Hospital, Boston, MA Project Title: AMPK: a potential target in prostate cancer / Source of Funding: AICF Fellowship Eric Snyder, M.D., Ph.D. / Postdoctoral Fellow, Tyler Jacks lab, MIT. Currently Assistant Professor of Pathology, UCSF, San Francisco, CA Project: DF/HCC SPORE in Breast Cancer. / Source of Funding: funding via BWH 2008 Alessandro Fornari, M.D. / Staff Pathologist, University of Turin, Italy Project: Responsible for a project aimed at the translation of gene expression profile signatures in paraffin embedded tissue. / Source of Funding: University of Turin, Italy 2008 Paul Nguyen, M.D. / Instructor in Radiation Oncology, Harvard Medical School and Attending Physician in Radiation Oncology BWH/DFCI Project Title: The Impact of p27 Expression on Outcome in RTOG / Source of Funding: RTOG Neil Martin, M.D. / Assistant Professor of Radiation Oncology/Harvard Medical School; and Attending at BWH, DFCI, CHB, Boston, MA Project Title: Investigation of PI3K activation in prostate cancer Bernadette Wildemore, M.D. / Physician in Anatomic & Clinical Pathology in Philadelphia, PA Project Title: Research Fellowship in the DF/BWH Center for Molecular Oncologic Pathology (CMOP) Shamini Selvarajah, Ph.D. / Clinical Cytogenetics Fellow, Harvard Medical School Genetics Training Program Project Title: Research Fellowship in the Center for Molecular Oncologic Pathology (CMOP). / Source of Funding: Industry: Nuclea Biomarkers, LLC 2009 Lance Ostrom / Dr. Loda served as Mr. Ostrom s thesis advisor at Harvard Extension School Thesis title: Relevance of sample handling in the assessment of PI3K activated targets in prostate cancer Michelangelo Fiorentino, M.D., Ph.D. / Director of the laboratory of oncologic molecular pathology S.Orsola-Malpighi Hospital, Bologna, Italy. Title: Associate Director for the Center for Molecular Oncologic Pathology (CMOP), Dana-Farber Cancer Institute/Brigham and Women s Hospital Natalia Scaglia, Ph.D. / Assistant Professor, The Biochemistry Research Institute of La Plata (INIBIOLP) Project Title: Fatty acid metabolism during the cell cycle Saumyadipta Pyne, Ph.D. / Resarch Scientist, Dana-Farber Cancer Institute, Boston, MA Project Title: Fatty acid synthase and prostate cancer Emma Cashman, M.D., Ph.D. / Resident, Surgical Otolaryngology, St. James Hospital. Dublin, Ireland Project title: The cause and consequence of centrosome and ploidy abnormalities in human cancers using barrett s Esophagus as a model; DNA methylaion of histones Michael Murphy, M.B. / Professor of Dermatology and Dermatopathology, University of Connecticut Stefano Sioletic, M.D. / Research Fellow, Dana-Farber Cancer Institute, Boston, MA Project title: Phamacodynamic profiling Debora Bastos, Ph.D. / Research Fellow, Dana-Farber Cancer Institute, Boston, MA 19

20 Project title: Genetic crosses of Pten and Fasn knock out mice Silvio Marques Zanata, M.D., Ph.D. / Associate Professor, Department of Basic Pathology, Federal University of Paraná, Brazil Project Title: Integrative models to define metabolic signatures in human prostate tumors: toward new antimetabolic approaches in cancer therapeutics present Nelma Gomes, Ph.D. / Research Fellow, Dana-Farber Cancer Institute, Boston, MA Project Title: Define the metabolic signature predictive of metastasis in prostate tumors driven by AKT/MYC alterations Formally Supervised Genito-Urinary Pathology Fellows Junyi Lei, M.D. / Anatomic Pathology & Clinical Pathology, Jdxpath Inc., Collegeville, PA Clinical Role: Genitourinary Fellow, Department of Pathology, Brigham and Women s Hospital Juan Miguel Mosquera, M.D., M.Sc. / Associate Professor of Pathology and Laboratory Medicine, Weill Cornell Medical College Clinical Role: Genitourinary Fellow, Department of Pathology, Brigham and Women s Hospital Saleem Umar, M.D. / Cytopathologist, Cleveland, OH Clinical Role: Genitourinary Fellow, Department of Pathology, Brigham and Women s Hospital Christopher Davidson, M.D. / Queen s University, Ontario Clinical Role: Genitourinary Fellow, Department of Pathology, Brigham and Women s Hospital Marcela Riveros-Angel, M.D. Clinical Role: Genitourinary Fellow, Department of Pathology, Brigham and Women s Hospital Trevor Flood, M.D. Clinical Role: Genitourinary Fellow, Department of Pathology, Brigham and Women s Hospital 2013-present Elizabeth Kehr, M.D. Clinical Role: Genitourinary Fellow, Department of Pathology, Brigham and Women s Hospital Formal Teaching of Peers (e.g., Continuing Medical Education and other continuing education courses) Formal Teaching of Peers 1991 Continuing medical education course, Director USL, Imola, Italy CME Course Molecuar biology applied to anatomic pathology 1995 Continuing medical education course, Faculty Florence, Italy. CME Course Molecular pathology and cytometry 1996 Harvard Medical School course. Modern Surgical Oncology. Boston, MA CME Course What the surgeon needs to know about breast cancer pathology 1996 Course on Automation in immunohistochemistry and in situ hybridization Treviso, Italy. Lectures: 1) In situ hybridization: principles and applications; 2) Expression and function of MAP kinase phosphatase in epithelial carcinogenesis; 3) Differential display-pcr-in situ Invited faculty. Lecturer 20